Almirall, S.A., a prominent global pharmaceutical company headquartered in Barcelona, Spain, has established itself as a leader in the dermatology and respiratory sectors since its founding in 1943. With a strong presence across Europe and the United States, Almirall focuses on developing innovative treatments that address unmet medical needs. The company’s core offerings include prescription medications and advanced therapies, particularly in dermatology, where it is renowned for its unique formulations and patient-centric approach. Almirall has achieved significant milestones, including strategic partnerships and a robust pipeline of products that enhance its market position. Recognised for its commitment to research and development, Almirall continues to make strides in improving patient outcomes and advancing healthcare solutions globally.
How does Almirall's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Almirall's score of 94 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Almirall, S.A. reported total greenhouse gas emissions of approximately 147,641,000 kg CO2e. This includes 5,742,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 3,752,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. The majority of their emissions, about 141,899,000 kg CO2e, fall under Scope 3, which includes all other indirect emissions in the value chain. Almirall has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2050, using 2019 as the baseline year. In the near term, the company is committed to reducing its absolute Scope 1 and 2 emissions by 50% by 2030. Additionally, they plan to reduce Scope 3 emissions by 28% within the same timeframe. Long-term targets include a 90% reduction in all scopes (1, 2, and 3) by 2050. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Almirall's commitment to sustainability within the pharmaceutical sector. The company is also dedicated to sourcing 100% renewable electricity annually through 2030, further supporting its climate action goals.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 6,864,000 | 0,000,000 | 000,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,305,000 | 0,000,000 | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 62,838,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Almirall's Scope 3 emissions, which decreased by 9% last year and increased by approximately 126% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 88% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Almirall has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Almirall's sustainability data and climate commitments